Kunxian capsules yields short-term clinical efficacy vs placebo for ankylosing spondylitis
Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trialTrials. 2016 Jul 22;17(1):337
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
80 patients with ankylosing spondylitis were randomized to receive a Chinese patent medicine, 0.6g Kunxian, or a placebo drug, 3 times daily for 12 weeks. The purpose of this study was to determine the efficacy of Kunxian, measured using the Assessment of SpondyloArthritis international Society (ASAS) 20 response rate. Other outcomes included ASAS 40, Bath Ankylosing Spondylitis Disease Activity I...
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.Continue